PRESCRIBING IN LIVER AND RENAL DISEASE

Size: px
Start display at page:

Download "PRESCRIBING IN LIVER AND RENAL DISEASE"

Transcription

1 THERAPEUTICS FOR INDEPENDENT PRESCRIBERS PRESCRIBING IN LIVER AND RENAL DISEASE Number 6 in a series of 15 articles on Therapeutics Aims and Objectives To outline the pathophysiological changes that occur in liver disease and renal disease and how they affect the pharmacokinetics and pharmacodynamics of commonly used medicines. To describe how prescribing should be modified in liver disease and renal disease in order to optimise drug efficacy and minimise toxicity. Additional Resources British National Formulary Drugs and the Liver. Merck Manual f Diagnosis and Therapy Kappel J and Calissi P. Safe drug prescribing for patients with renal insufficiency CMAJ. 2002;166: Pathophysiology of Liver disease The liver is the largest organ that eliminates medicines and it is, quantitatively, by far the most important, although the skin, gut, lungs, kidney and white cells have some limited capacity to clear medicines. Many drugs are lipid soluble (this is necessary for them to cross lipid membranes and reach their site of action). Lipid soluble drugs generally tend to Page 1 of 11

2 be substantially protein-bound in the blood and cannot therefore be effectively cleared by glomerular filtration in the kidney. Although unbound lipid-soluble medicine can cross the glomerulus, even that portion tends to be passively reabsorbed through the renal tubular cell, down a concentration gradient. Several metabolic pathways therefore exist to convert these agents to more water-soluble metabolites in the liver. These water soluble metabolites are, in general, less active than the parent compound, although there are several important exceptions. Phase 1 metabolism involves the mono-oxygenase system in the smooth endoplasmic reticulum of the hepatocytes (the principal liver cells). Here, a variety of subtypes of cytochrome P450 enzymes (CYP450) catalyze oxidation, reduction, hydrolysis and dealkylation reactions. These enzymes are not specific and drugs may compete with each other for metabolism via one particular pathway. A given drug may be metabolized via several routes mediated by several subtypes of CYP450. Phase 2 metabolism involves the conjugation of parent drug or metabolite with a watersoluble molecule such as glucuronic acid (glucuronidation), sulphate, amino acid such as glutathione or glycine, or acetyl coenzyme A (acetylation). As with phase 1 reactions, the metabolites are generally less active and therefore of low toxicity, but there are important exceptions. The liver has a significant capacity to perform phase 2 reactions, although there is also some, more limited, activity in the gut wall. Finally, drugs with a high molecular weight (e.g. rifampicin) may be excreted in the bile, particularly as conjugates. The drug or its conjugate may be reabsorbed, either directly or after deconjugation by intestinal microflora, resulting in an enterohepatic recycling, which Page 2 of 11

3 offsets the effects of biliary excretion. In obstructive jaundice, enterohepatic circulation is impaired, leading to an accumulation of drugs excreted in the bile (e.g. rifampicin and fusidic acid). Chronic liver disease is often associated with an impairment of drug metabolism and, in particular, phase 1 metabolic processes. The effect of impairment of metabolism in liver disease will be greater for those drugs with extensive presystemic (first pass) metabolism. The bioavailability (see Principles of Therapeutics) of propranolol is much greater in patients with chronic liver disease, not because of better absorption (absorption is virtually complete) but because it cannot be efficiently metabolised when all that is absorbed passes through the liver for the first time. This reduction in the "first-pass effect" is due not only to the reduced metabolic activity of the hepatocytes, but also to intra- and extra-hepatic shunting of blood past those liver cells and also due to a reduction in effective liver blood flow (normally 1.5 l/min in healthy individuals) in liver disease. In addition, plasma albumin concentrations may fall in liver disease since this important plasma protein is produced by the liver. Low albumin concentrations may mean that the total drug concentration may underestimate the free (active) drug concentration in plasma, because of a reduced extent of plasma protein binding (e.g. diphenylhydantoin). Measurement of free drug concentration may therefore be useful in such circumstances (see Monitoring of Drug Therapy). Pharmacodynamic changes also occur in liver disease. There is a reduced production of vitamin K-dependent clotting factor, leading to increased warfarin sensitivity. Encephalopathy can be precipitated by drugs causing electrolyte disturbance (e.g. thiazide Page 3 of 11

4 diuretics) and by opiates and other psychoactive drugs, because of increased cerebral sensitivity. Prescribing in Liver Disease Important factors to consider include the extent of liver dysfunction, the type of disease, and whether decompensation (i.e. the presence of overt clinical complications such as jaundice or ascites) is present. The INR is a useful measure of acute hepatic damage (e.g. in paracetamol-induced hepatotoxicity) but the serum albumin is a better long-term marker. In liver disease, the serum albumin concentration correlates roughly with the degree of impairment of drug metabolism (i.e. the lower the albumin the more severe the impairment). Liver transaminases (i.e. alanine amnotransferase [ALT] and aspartate aminotransferase [AST]) are poor indicators of the extent of liver damage, since they may be normal, even when there is extensive liver dysfunction. Practical Prescribing Hints in liver disease For the reasons outlined above, the following guidelines can be usefully applied when prescribing to patients with liver disease: Avoid hepatotoxic drugs, (type A and type B ADRs are more common in the setting of liver disease) See Table 1 below. Table 1: Drugs causing acute liver failure Commonest causes Paracetamol, halothane, isoniazid, rifampicin, NSAIDs, sulphonamides, sodium valproate, carbamazepine, flutamide, 3, 4-methylenedioxymethamphetamine ( Ecstasy ). Less frequent or historical causes Phenytoin, isoflurane, enflurane, tetracycline, allopurinol, ketoconazole, monoamine oxidase inhibitors (MAOIs), disulfiram, methyldopa, amiodarone, tricyclic antidepressants, propylthiouracil, gold, 2, 3-dideoxyinosine (ddi). Richardson P, O Grady JG. Diseases of the liver: Acute liver disease. Hospital Pharmacist 2002; 9: Page 4 of 11

5 if possible use drugs not metabolised by the liver. Renally excreted drugs are preferred as long as renal function is normal and is being monitored. avoid drugs causing fluid retention (NSAIDs), normal saline infusions and drugs requiring hepatic activation. Avoid or exercise extreme caution with drugs that increase the risk of bleeding, depending on the severity of the liver disease. use the BNF as a guide, or ask your local medicines information pharmacist for further advice. Pathophysiology of Renal Disease The kidneys are the major route of excretion of many metabolites of commonly used medicines. Some of these metabolites may be active and, therefore, kidney dysfunction may be associated with enhanced effect. Since many drugs are lipid soluble, however, it is often not until they are metabolised by other organs (e.g. the liver) that they can be excreted in the urine. Thus there are relatively few widely used medicines that are predominantly excreted by the kidney in unchanged form. They tend to be water soluble agents which are relatively poorly protein bound in the blood. There are three main mechanisms that affect the extent of renal excretion: Glomerular filtration Small drug or metabolite molecules may undergo the passive process of glomerular filtration into the urinary space in the glomerulus, through pores in the glomerular capillary endothelial cells. This, however, only applies to free (unbound) drug in blood and not drugs bound to plasma proteins. The glomerular filtration rate (GFR) is the parameter that Page 5 of 11

6 is used to express degree of renal function and is the rate at which plasma is filtered through the glomeruli. In a healthy adult, the normal GFR is about 120 ml/min. The clearance of creatinine (a waste product of muscle turnover) is very similar to the GFR in any particular individual and can, therefore be used to estimate GFR. Active Tubular Secretion Tubular secretion is an active (energy-dependent) process by which some acids and bases are transported into tubular fluid against a concentration gradient. Competition for this relatively nonspecific process between two acidic or two basic drugs may lead to diminished excretion of one or both agents, resulting in drug interactions (see Drug Interactions). Tubular reabsorption This passive process ensures that many drugs (particularly highly lipid-soluble drugs) will be rapidly reabsorbed from the kidney tubule. Since around 99% of the water filtered through the glomerulus is reabsorbed in the kidney tubule, there is a resultant concentrating effect and an increase in drug reabsorption. This effect can be reduced to a small extent by increasing urine flow. Changes in urine ph will have significant effects on reabsorption of weak acids and bases. The excretion of weak acids will be increased in alkaline urine and of weak bases in acid urine. Thus reabsorption may be altered in conditions where the urine ph may be affected (e.g. renal tubular acidosis). Renal disease is associated predominantly with a fall in GFR, with active renal tubular secretion mechanisms less affected. Measurement of serum creatinine or creatinine clearance is, therefore, useful in calculating the optimum dose of drugs excreted Page 6 of 11

7 predominantly by glomerular filtration. Measurement of GFR is of less value for drugs such as penicillins, which are largely actively secreted at the proximal renal tubule. Active tubular secretion is relatively spared until the late stages of renal impairment so that for those drugs in which this process contributes significantly to total clearance (e.g. penicillins such as amoxicillin), dose-reduction may not be necessary until the renal impairment is severe. The major pharmacodynamic effect seen in renal disease is the enhanced blood brain barrier permeability to opiates, benzodiazepines and other psychoactive drugs. In renal failure, there is an accumulation of toxic waste products, eventually resulting in severe uraemia and encephalopathy with confusion, loss of memory and other neurological signs. It is thought that purine metabolites, amines, indoles, phenols and other substances may contribute to uraemia and retained middle molecules (molecular weight Da) may also contribute to the problem. It is likely that subclinical accumulation of these or other agents may contribute to the increased sensitivity to psychoactive drugs, particularly opioids, although pharmacokinetic factors (e.g. accumulation of active metabolites) may also be important for several drugs. Defining renal impairment In renal disease glomerular filtration rate declines progressively and is generally defined as follows: Grade Mild Moderate Severe GFR 20-50ml/min 10-20ml/min <10ml/min For further information see British National Formulary Appendix 3: Renal Impairment Page 7 of 11

8 Prescribing in Renal Disease In renal dysfunction, the creatinine clearance is closely related and similar in magnitude to the GFR. Thus GFR can be calculated by measuring the patient s serum creatinine (which has little diurnal variation) and age, gender and body weight. The Cockcroft Gault equation uses the relationship: Creatinine clearance = [140 - age(y)] x Body weight (kg) 0.82 x plasma creatinine (umol/l) For females, who have less muscle mass at any given weight, the final result must be multiplied by This equation is relevant only when the renal function is relatively constant and in the absence of concomitant liver disease. The method is not reliable in children or pregnancy. It is a useful guide to dose adjustment in renal disease and in the elderly when glomerular filtration is the major renal excretory mechanism. When using this equation for obese patients, the ideal body weight (IBW) should be used because adipose tissue (or fat) does not produce creatinine. The IBW can be estimated using the following equations IBW in kg (male) = IBW in kg (female) = 50+ (2.3 x height in inches over 5 feet) (2.3 x height in inched over 5 feet) The proportional dose adjustment will also depend upon the proportion of the drug excreted unchanged by the kidney (F) (since some drug may be cleared by metabolic pathways) in the following formula: Page 8 of 11

9 Equation 2. Dose (as proportion of normal) = (1-F) + F * GFR (patient) GFR (normal) This relationship can be used to aid in the calculation of the dose of digoxin or gentamicin, for example. The situation is more difficult if renal tubular secretion is a major excretory mechanism since no clinically applicable direct measurements of this pathway are available. In patients with renal disease, several outcomes may occur. Toxicity may occur because of failure to excrete an active agent or its (active or toxic) metabolites. Pharmacodynamic sensitivity may result in enhanced toxicity even if elimination of that particular agent is not impaired. In addition patients with renal failure may not tolerate adverse effects as well as patients with normal renal function so the outcome of any ADR may be more serious Many of these problems can be avoided by reducing the dose or by using alternative drugs. Drugs and dialysis Dialysis (haemo- or peritoneal) is a type of renal replacement therapy, usually indicated when the kidneys are barely or non-functional. The aim of renal relacement therapies is to remove toxins and excess fluid, and to correct biochemical disturbances. The removal of a drug by dialysis depends on a number of factors: Molecular weight Protein binding Water solubility Drugs below molecular weight 500 dialyse easily Highly protein bound drugs e.g. warfarin are not easily dialysed Because dialysis solutions are aqueous, water-soluble drugs enter them preferentially and fat soluble drugs e.g. thiopentone do not dialyse easily. Page 9 of 11

10 Vol. of distribution Drugs with large Vd s dialyse slowly (e.g. nortriptyline) and dose adjustment of such drugs is not normally necessary in this situation. Practical Prescribing Hints in Renal Disease Avoid nephrotoxic drugs (e.g. tetracyclines)in patients with renal disease because the consequences of nephrotoxicity are likely to be more serious when the renal reserve is already reduced. Use tables (e.g. in BNF a guide to dosage reduction.) Creatinine clearance can be calculated as shown above. Dosage reduction can be achieved by reducing the size of dose or by increasing the interval between doses. Loading doses remain important since half-life (t½) and hence time to reach steady state concentration (4-5 half lives) will be greatly increased for renally handled drugs Avoid drugs which cause fluid retention (e.g. NSAIDS) Ask your local medicines information pharmacist for further advice. Page 10 of 11

11 INDEPENDENT PRESCRIBING PRESCRIBING IN LIVER AND RENAL DISEASE CASE STUDY Name: Profession: nurse/pharmacist (please delete as appropriate) Mr H J, a 75 year old man weighing 65kg (height 1.73m) is being treated for chronic heart failure with furosemide and digoxin 0.125mg daily. His serum creatinine is 260µmol/l. He complains of severe pain and swelling of his right 1st metatarsophalyngeal joint and you find his serum urate to be raised at 0.6mmol/l. He says this has occurred on two other occasions in the last 6 months. He is otherwise symptom- free. 1.a. What is your initial diagnosis of his symptoms? 1.b. How would you confirm this? 1.c. What would you want to exclude? 2. What new treatment, if any, would you give including doses and durations? a. For this acute problem.. b. For long term treatment? 3. Comment on his long-standing drug therapy. Page 11 of 11

Renal Excretion of Drugs

Renal Excretion of Drugs Renal Excretion of Drugs 3 1 Objectives : 1 Identify main and minor routes of Excretion including renal elimination and biliary excretion 2 Describe its consequences on duration of drugs. For better understanding:

More information

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College Excretion of Drugs Prof. Hanan Hagar Pharmacology Unit Medical College Excretion of Drugs By the end of this lecture, students should be able to! Identify main and minor routes of excretion including renal

More information

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK) Unit 2b: EXCRETION OF DRUGS By Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK) Excretion, along with metabolism and tissue redistribution,

More information

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal

More information

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion 59-291 Section 1, Lecture 5 Drug Excretion -most drugs are excreted in urine either as unchanged or drug metabolites Renal Function 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular

More information

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal

More information

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Pharmacokinetics of Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Absorption Is the transfer of a drug from its site of administration to the bloodstream.

More information

Using the BNF. CWFS F1 Programme Safe Prescribing Module

Using the BNF. CWFS F1 Programme Safe Prescribing Module Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of

More information

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics

More information

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe

More information

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein

More information

Pharmacokinetics. Karim Rafaat

Pharmacokinetics. Karim Rafaat Pharmacokinetics Karim Rafaat Pharmacokinetics The therapeutic effect of a drug is determined by the concentration of drug at the receptor site of action. Even though the concentration of drug that reaches

More information

Industrial Toxicology

Industrial Toxicology Industrial Toxicology Learning Objectives Know the assumptions of the doseresponse and time-course curves Be able to define and label key points of a curve Know the difference between potency and efficacy

More information

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester Basic Concepts in Pharmacokinetics Leon Aarons Manchester Pharmacy School University of Manchester Objectives 1. Define pharmacokinetics 2. Describe absorption 3. Describe distribution 4. Describe elimination

More information

PHAR 7632 Chapter 16

PHAR 7632 Chapter 16 PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes

More information

Definition of bilirubin Bilirubin metabolism

Definition of bilirubin Bilirubin metabolism Definition of bilirubin Bilirubin metabolism obilirubin formation otransport of bilirubin in plasma ohepatic bilirubin transport oexcretion through intestine Other substances conjugated by glucuronyl transferase.

More information

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects

More information

Non-protein nitrogenous substances (NPN)

Non-protein nitrogenous substances (NPN) Non-protein nitrogenous substances (NPN) A simple, inexpensive screening test a routine urinalysis is often the first test conducted if kidney problems are suspected. A small, randomly collected urine

More information

Metabolism. Objectives. Metabolism. 26 July Chapter 28 1

Metabolism. Objectives. Metabolism. 26 July Chapter 28 1 Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect

More information

Ibuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN

Ibuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN Ibuprofen Ibuprofen and Paracetamol: prescribing overview Sarah Holloway Macmillan CNS in palliative care NSAID Non-selective COX inhibitor Oral bioavailability: 90% Onset of action: 20-30 mins (can take

More information

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

DIABETES AND LABORATORY TESTS. Author: Josephine Davis DIABETES AND LABORATORY TESTS Author: Josephine Davis LAB TESTS Think twice before you test. What is the reason for testing? Laboratory tests are generally requested in primary care for one of the following

More information

Kidney Physiology. Mechanisms of Urine Formation TUBULAR SECRETION Eunise A. Foster Shalonda Reed

Kidney Physiology. Mechanisms of Urine Formation TUBULAR SECRETION Eunise A. Foster Shalonda Reed Kidney Physiology Mechanisms of Urine Formation TUBULAR SECRETION Eunise A. Foster Shalonda Reed The purpose of tubular secrection To dispose of certain substances that are bound to plasma proteins. To

More information

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali 10 Tamer Barakat Abdul Aziz ALShamali Abdul Aziz ALShamali Dr. Alia Elimination: Refampin is used to treat TB not malaria (Quinacrine is used for malaria) It s the opposite process of absorption. It's

More information

(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD

(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD Kidney Function Tests (KFTs) IACLD CME, Monday, February 20, 2012 Mohammad Reza Bakhtiari, DCLS, PhD Iranian Research Organization for Science & Technology (IROST) Tehran, Iran Composition and Properties

More information

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW: Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic

More information

KD02 [Mar96] [Feb12] Which has the greatest renal clearance? A. PAH B. Glucose C. Urea D. Water E. Inulin

KD02 [Mar96] [Feb12] Which has the greatest renal clearance? A. PAH B. Glucose C. Urea D. Water E. Inulin Renal Physiology MCQ KD01 [Mar96] [Apr01] Renal blood flow is dependent on: A. Juxtaglomerular apparatus B. [Na+] at macula densa C. Afferent vasodilatation D. Arterial pressure (poorly worded/recalled

More information

The principal functions of the kidneys

The principal functions of the kidneys Renal physiology The principal functions of the kidneys Formation and excretion of urine Excretion of waste products, drugs, and toxins Regulation of body water and mineral content of the body Maintenance

More information

INTRODUCTION TO PHARMACOKINETICS

INTRODUCTION TO PHARMACOKINETICS INTRODUCTION TO PHARMACOKINETICS 1 http://www.biology.iupui.edu/biocourses/biol540/4pipeline2css.html 2 PHARMACOKINETICS 1. ABSORPTION 2. DISTRIBUTION 3. METABOLISM 4. EXCRETION ALL THESE PROCESSES ARE

More information

BACKGROUND Measuring renal function :

BACKGROUND Measuring renal function : A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal

More information

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase

More information

DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION

DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION ROUTE OF DRUG ADMINISTRATION AND EXTRAHEPATIC DRUG METABOLISM The decline in plasma concentration after drug administration

More information

PHA5128 Dose Optimization II Case Study I Spring 2013

PHA5128 Dose Optimization II Case Study I Spring 2013 Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated

More information

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral

More information

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage

More information

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention

More information

Appendix 5: Hepatic impairment

Appendix 5: Hepatic impairment Appendix 5: Hepatic impairment Liver disease may alter the response to drugs. However, the hepatic reserve appears to be large and liver disease has to be severe before important changes in drug metabolism

More information

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations Selected Clinical Calculations Chapter 10 Heparin-Dosing calculations Heparin is a heterogeneous group of muco-polysaccharides that have anticoagulant properties (slows clotting time). Heparin salt, as

More information

METABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

METABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84 METABOLISM Ali Alhoshani, B.Pharm, Ph.D. ahoshani@ksu.edu.sa Office: 2B 84 Metabolism By the end of this lecture, you should: Recognize the importance of biotransformation Know the different sites for

More information

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11 Metformin Associated Lactic Acidosis Jun-Ki Park 9/6/11 Probably the most common mechanism by which metformin elevates blood lactate is by inducing catecholamine release in those who regulate or prescribe

More information

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition Chapter Questions Modern Pharmacology With Clinical Applications Sixth Edition Mechanism of Drug Action Questions 1. Receptors are macromolecules that a. Are designed to attract drugs b. Are resistant

More information

Click to edit Master title style

Click to edit Master title style A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why

More information

1.2 Synonyms There are several synonyms e.g. diaminomethanal, but in a medical context, this substance is always referred to as urea.

1.2 Synonyms There are several synonyms e.g. diaminomethanal, but in a medical context, this substance is always referred to as urea. Urea (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Urea 1.2 Synonyms There are several synonyms e.g. diaminomethanal, but in a medical context, this substance is always referred

More information

Pharmacokinetics Dr. Iman Lec. 3

Pharmacokinetics Dr. Iman Lec. 3 Pharmacokinetics r. Iman Lec. 3 Pharmacokinetics A dequate drug doses must be delivered to the target organ to get therapeutic but not toxic levels. So, pharmacokinetic examines the movement of drug over

More information

AMINOGLYCOSIDES TDM D O N E B Y

AMINOGLYCOSIDES TDM D O N E B Y AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.

More information

Renal Function and Associated Laboratory Tests

Renal Function and Associated Laboratory Tests Renal Function and Associated Laboratory Tests Contents Glomerular Filtration Rate (GFR)... 2 Cockroft-Gault Calculation of Creatinine Clearance... 3 Blood Urea Nitrogen (BUN) to Serum Creatinine (SCr)

More information

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell 1 Rational Dose Prediction Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Pharmacology Pharmacology is derived from a Greek word (pharmakon). The Greeks used

More information

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?

More information

StRs and CT doctors in haematology. September Folinic acid dose modified.

StRs and CT doctors in haematology. September Folinic acid dose modified. High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH

More information

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,

More information

RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.

RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D. RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D. Learning Objectives 1. Identify the region of the renal tubule in which reabsorption and secretion occur. 2. Describe the cellular

More information

Ch 19: The Kidneys. Functional unit of kidneys:?? Developed by John Gallagher, MS, DVM

Ch 19: The Kidneys. Functional unit of kidneys:?? Developed by John Gallagher, MS, DVM Ch 19: The Kidneys Homeostatic regulation of ECF volume and BP Osmolarity 290 mosm Ion balance Na+ and K+, etc. ph (acid-base balance Excretion of wastes & foreign substances Hormone production EPO Renin

More information

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,

More information

Drug dosing in Extremes of Weight

Drug dosing in Extremes of Weight Drug dosing in Extremes of Weight The Plump & Heavy versus The Skinny & Light Maria Minerva P. Calimag, MD, MSc, PhD, DPBA, FPSECP PROFESSOR Departments of Pharmacology, Anesthesiology and Clinical Epidemiology

More information

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile

More information

Pharmacokinetics Metabolism

Pharmacokinetics Metabolism Pharmacokinetics Metabolism Learning object Know the processes involved in ADME of drugs Know how these processes may affect the action of xenobiotics Appreciate how these processes can affect the outcome

More information

General pharmacology Lecture(3)

General pharmacology Lecture(3) General pharmacology Lecture(3) 2. Specialized transport: It may be: i. Carrier-mediated transport ii. Pinocytosis. i. Carrier-mediated transport: The drug combines with a carrier (a specialized protein

More information

Excretory System 1. a)label the parts indicated above and give one function for structures Y and Z

Excretory System 1. a)label the parts indicated above and give one function for structures Y and Z Excretory System 1 1. Excretory System a)label the parts indicated above and give one function for structures Y and Z W- X- Y- Z- b) Which of the following is not a function of the organ shown? A. to produce

More information

TDM. Measurement techniques used to determine cyclosporine level include:

TDM. Measurement techniques used to determine cyclosporine level include: TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.

More information

B. Incorrect! Compounds are made more polar, to increase their excretion.

B. Incorrect! Compounds are made more polar, to increase their excretion. Pharmacology - Problem Drill 04: Biotransformation Question No. 1 of 10 Instructions: (1) Read the problem and answer choices carefully, (2) Work the problems on paper as 1. What is biotransformation?

More information

Variation in drug responses & Drug-Drug Interactions

Variation in drug responses & Drug-Drug Interactions Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Tipol 75mg Suppositories Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 75mg of paracetamol For a full list of excipients,

More information

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

Renal System Dr. Naim Kittana Department of Biomedical Sciences Faculty of Medicine & Health Sciences An-Najah National University

Renal System Dr. Naim Kittana Department of Biomedical Sciences Faculty of Medicine & Health Sciences An-Najah National University Renal System Dr. Naim Kittana Department of Biomedical Sciences Faculty of Medicine & Health Sciences An-Najah National University Declaration The content and the figures of this seminar were directly

More information

PHA First Exam Fall 2003

PHA First Exam Fall 2003 PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts

More information

BIOL 2402 Renal Function

BIOL 2402 Renal Function BIOL 2402 Renal Function Dr. Chris Doumen Collin County Community College 1 Renal Clearance and GFR Refers to the volume of blood plasma from which a component is completely removed in one minute by all

More information

Drug elimination and Hepatic clearance Chapter 6

Drug elimination and Hepatic clearance Chapter 6 Drug elimination and Hepatic clearance Chapter 6 DRUG ELIMINATION Drugs are removed from the body by various elimination processes. Drug elimination refers to the irreversible removal of drug from the

More information

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does

More information

Section 5.2: Pharmacokinetic properties

Section 5.2: Pharmacokinetic properties Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group

More information

Effects of Liver Disease on Pharmacokinetics

Effects of Liver Disease on Pharmacokinetics Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver

More information

PHA First Exam. Fall 2004

PHA First Exam. Fall 2004 PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem

More information

Dr.Nahid Osman Ahmed 1

Dr.Nahid Osman Ahmed 1 1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),

More information

BASIC PHARMACOKINETICS

BASIC PHARMACOKINETICS BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter

More information

BCH 450 Biochemistry of Specialized Tissues

BCH 450 Biochemistry of Specialized Tissues BCH 450 Biochemistry of Specialized Tissues VII. Renal Structure, Function & Regulation Kidney Function 1. Regulate Extracellular fluid (ECF) (plasma and interstitial fluid) through formation of urine.

More information

Ch 17 Physiology of the Kidneys

Ch 17 Physiology of the Kidneys Ch 17 Physiology of the Kidneys Review Anatomy on your own SLOs List and describe the 4 major functions of the kidneys. List and explain the 4 processes of the urinary system. Diagram the filtration barriers

More information

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1 Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance BCH472 [Practical] 1 -Kidney functions: - The kidneys serve three essential functions: 1. They function as filters, removing metabolic

More information

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 1 Outline Definition & Relevance of Pharmacokinetics

More information

DIURETICS-4 Dr. Shariq Syed

DIURETICS-4 Dr. Shariq Syed DIURETICS-4 Dr. Shariq Syed AIKTC - Knowledge Resources & Relay Center 1 Pop Quiz!! Loop diuretics act on which transporter PKCC NKCC2 AIKTCC I Don t know AIKTC - Knowledge Resources & Relay Center 2 Pop

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and

More information

Human Urogenital System 26-1

Human Urogenital System 26-1 Human Urogenital System 26-1 Urogenital System Functions Filtering of blood, Removal of wastes and metabolites Regulation of blood volume and composition concentration of blood solutes ph of extracellular

More information

A. Correct! Flushing acids from the system will assist in re-establishing the acid-base equilibrium in the blood.

A. Correct! Flushing acids from the system will assist in re-establishing the acid-base equilibrium in the blood. OAT Biology - Problem Drill 16: The Urinary System Question No. 1 of 10 1. Which of the following would solve a drop in blood ph? Question #01 (A) Decreased retention of acids. (B) Increased excretion

More information

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties

More information

1. a)label the parts indicated above and give one function for structures Y and Z

1. a)label the parts indicated above and give one function for structures Y and Z Excretory System 1 1. Excretory System a)label the parts indicated above and give one function for structures Y and Z W- renal cortex - X- renal medulla Y- renal pelvis collecting center of urine and then

More information

Pharmacology in the Elderly

Pharmacology in the Elderly Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol

More information

Infective Liver Disease

Infective Liver Disease The Role oeofdrugs in Non Infective Liver Disease Peter Tenni Senior Lecturer in Therapeutics, School of Pharmacy University of Tasmania Senior Research Fellow Unit for Medication Outcomes Research and

More information

Bilirubin Metabolism. Prof. Dr. Hedef Dhafir El-Yassin. 1 Prof. Dr. El-Yassin

Bilirubin Metabolism. Prof. Dr. Hedef Dhafir El-Yassin. 1 Prof. Dr. El-Yassin Bilirubin Metabolism Prof. Dr. Hedef Dhafir El-Yassin 1 Prof. Dr. El-Yassin Objectives: 1. To outline the basic metabolic pathway of bilirubin breakdown and conjugation 2. To state the basic metabolic

More information

WEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47

WEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47 MPharm Programme Acute Kidney Injury Alan M. Green 2017 Slide 1 of 47 Overview Renal Function What is it? Why does it matter? What causes it? Who is at risk? What can we (Pharmacists) do? How do you recognise

More information

egfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31

egfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31 Update on Renal Therapeutics Caroline Ashley Lead Pharmacist Renal Services UCL Centre for Nephrology, Royal Free Hospital, London Kongress für Arzneimittelinformation January 2011 What are we going to

More information

PHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84

PHARMACOLOGY-1 PHL-313. Ali Alhoshani   Office: 2B 84 PHARMACOLOGY-1 PHL-313 Ali Alhoshani ahoshani@ksu.edu.sa http://fac.ksu.edu.sa/ahoshani Office: 2B 84 General rules Reference: General rules Email [PHL313-1 st Semester 38-39] Student ID- Question Example

More information

Introduction to Clinical Diagnosis Nephrology

Introduction to Clinical Diagnosis Nephrology Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College

More information

Introducing Pharmacokinetics and Pharmacodynamics. Janice Davies Pharmacist Room 23 Maudland Building

Introducing Pharmacokinetics and Pharmacodynamics. Janice Davies Pharmacist Room 23 Maudland Building Introducing Pharmacokinetics and Pharmacodynamics Janice Davies Pharmacist Room 23 Maudland Building JADavies5@uclan.ac.uk 1 elearn 2 DVD Any problems / questions? 3 Learning outcomes Define and discuss

More information

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal

More information

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook

More information

DRUG DISTRIBUTION. Distribution Blood Brain Barrier Protein Binding

DRUG DISTRIBUTION. Distribution Blood Brain Barrier Protein Binding DRUG DISTRIBUTION Distribution Blood Brain Barrier Protein Binding DRUG DISTRIBUTION Drug distribution is a reversible transport of drug through the body by the systemic circulation The drug molecules

More information

Functional morphology of kidneys Clearance

Functional morphology of kidneys Clearance Functional morphology of kidneys Clearance Assoc. Prof. MUDr. Markéta Bébarová, Ph.D. Department of Physiology Faculty of Medicine, Masaryk University This presentation includes only the most important

More information

EXCRETION QUESTIONS. Use the following information to answer the next two questions.

EXCRETION QUESTIONS. Use the following information to answer the next two questions. EXCRETION QUESTIONS Use the following information to answer the next two questions. 1. Filtration occurs at the area labeled A. V B. X C. Y D. Z 2. The antidiuretic hormone (vasopressin) acts on the area

More information

Renal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November

Renal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November Renal Transporters- pathophysiology of drug - induced renal disorders Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November Renal Failure Up to 25% of acute renal failure is drug induced

More information

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors.

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors. Overview The Kidneys Nicola Barlow Clinical Biochemistry Department City Hospital Renal physiology Renal pathophysiology Acute kidney injury Chronic kidney disease Assessing renal function GFR Proteinuria

More information

6. Production or formation of plasma protein and clotting factors and heparin.

6. Production or formation of plasma protein and clotting factors and heparin. Liver function test Clinical pathology dr. Ali H. Liver function test The liver has many vital physiologic functions involving synthesis, excretion, and storage. When a disease process damages cells within

More information

Lecture-2 Review of the previous lecture:

Lecture-2 Review of the previous lecture: Lecture-2 Review of the previous lecture: -Kidney s function is to clean the blood by the removing of the waste plus adding some valuable substances -kidney failure will lead to death for many reasons,

More information